Introduction
============

*Staphylococcus aureus* is a normal flora of human beings and other animals. It is also an opportunistic pathogen generally found in human beings in areas such as skin, nose, throat, mouth, and intestinal tract, causing mild-to-life-threatening diseases such as endocarditis, sepsis, soft tissue injury, urinary tract infection, respiratory tract infection, intestinal tract infection, and bloodstream infections.[@b1-idrt-9-2016-011],[@b2-idrt-9-2016-011] *S. aureus* is ubiquitous commensal gram-positive cocci on human skins and the anterior part of the body, but it frequently causes surgical wound infections with high prevalence rate ranging from 4.6% to 54.4% worldwide.[@b3-idrt-9-2016-011],[@b4-idrt-9-2016-011] To control *S. aureus* infection, different antibiotics are used, but recently, several antibiotics are not working against *S. aureus* infection because they are capable to resist these antibiotics. *S. aureus* has developed resistance to most classes of antimicrobial agents. Before 1944, penicillin was used to treat staphylococcal infection but, in 1944, first penicillin-resistant *S. aureus* was isolated. They produce penicillinase enzyme that destroys the penicillin.[@b5-idrt-9-2016-011] Nowadays, \>90% *S. aureus* strains are resistant to penicillin.[@b6-idrt-9-2016-011] Later on, a semisynthetic penicillin known as methicillin was used to treat penicillin-resistant *S. aureus*. In 1962, methicillin was also resistant to *S. aureus*. In India, the prevalence rate of methicillin-resistant *S. aureus* (MRSA) is high in hospitals.[@b7-idrt-9-2016-011] Due to MRSA appeared, a glycopeptide antibiotic known as vancomycin was used to treat MRSA. In 1996, first intermediate resistance to vancomycin was reported,[@b8-idrt-9-2016-011] and in June 2002, resistance finally emerged first in USA. This resistance appeared because vancomycin-resistant *S. aureus* (VRSA) contains *vanA* gene and *mecA* gene.[@b9-idrt-9-2016-011] In India, first VRSA was found in Kolkata in 2005.[@b10-idrt-9-2016-011] To overcome this drug resistance and to treat the *S. aureus* infection, there is an urgent need to identify the antibiotic resistance pattern of bacteria and to develop a new kind of antimicrobial agent for proper management of *S. aureus*-infected patients.

Eugenol is a major phytochemical of clove oil and is primarily used as a flavoring agent in food and cosmetic products. Many studies revealed that eugenol shows excellent antimicrobial, antioxidant, and anti-inflammatory activities.[@b11-idrt-9-2016-011],[@b12-idrt-9-2016-011] It has been known that different antibiotics can influence the expression of staphylococcal exotoxins. Therefore, the goal of this study was to assess the function of eugenol on VRSA. For this purpose, the *S. aureus* strains are isolated from pus samples, identified on the basis of physiological or biochemical characteristics according to Bergeys Manual of Systematic Bacteriology,[@b13-idrt-9-2016-011]--[@b15-idrt-9-2016-011] characterized by traditional biochemical reactions, and observed antibiotic resistance patterns of isolated *S. aureus* strains against some conventional and traditional antibiotics, including vancomycin, to identify VRSA. In developing countries, phenotypic tests are used in the diagnosis of staphylococcal infections.

Materials and Methods
=====================

Culture media, chemicals, and quality control strains
-----------------------------------------------------

All the culture media, crystal violet, Lugol's iodine, safranine, *N*,*N*,*N*′,*N*′-tetramethyl-*p*-phenylenediamine dihydrochloride, latex agglutination reagent, and antibiotic disks were purchased from HiMedia. Sodium chloride (NaCl), hydrogen peroxide (H~2~O~2~), sucrose, potassium dihydrogen phosphate (KH~2~PO~4~), and dipotassium hydrogen phosphate (K~2~HPO~4~) were procured from Merck Ltd. and SRL Pvt. Ltd. All other chemicals were from Merck Ltd. and SRL Pvt. Ltd. and were the highest grade available.

Different standard bacterial strains such as *S. aureus* ATCC 25923, *Staphylococcus epidermidis* ATCC 12228, *Escherichia coli* ATCC 23509, and *Enterococcus faecalis* ATCC were obtained from Microbiology Laboratory at Midnapore Medical College and Hospital and Microbiology Laboratory at University of Calcutta. These strains were stored in agar slants at 4°C for further studies and used as reference strains.

Collection, transport, and culture of sample
--------------------------------------------

A total of 36 pus samples were collected from male outpatients, with the age range of 18--40 years who attended nearby hospital, after proper inquiry of their infection history and treatment summary between June 2013 and November 2014. All the patients enrolled in this study signed informed consent and were from low socioeconomic population. Inpatients, previously admitted patients, and postoperative patients were excluded from the study. Samples were collected using autoclaved sterile vials directly by using swab sticks. These samples were then transported to the laboratory within two hours of collection.[@b16-idrt-9-2016-011] The whole study protocol was approved by the Institutional Ethical Committee, Vidyasagar University, Midnapore, and conducted in accordance with the principles of the Declaration of Helsinki.

Isolation and identification of *S. aureus*
-------------------------------------------

The samples kept in Luria broth was incubated in a shaking incubator at 37°C for 24 hours. Bacterial cultures were found growing on nutrient agar media. The samples were then purified by single-colony isolation technique on nutrient agar.[@b10-idrt-9-2016-011] Isolates were subcultured on tryptic soy agar plates containing 5% sheep blood agar and incubated at 37°C for 16--24 hours for characterization studies. On the basis of colony morphology, gram staining, and different biochemical reactions, the organisms were identified as *S. aureus*.[@b15-idrt-9-2016-011]--[@b25-idrt-9-2016-011]

Antimicrobial susceptibility testing
------------------------------------

Antimicrobial susceptibility testing of clinical isolates was done by Kirby--Bauer disk diffusion method as recommended by the Clinical Laboratory Standards Institute guidelines.[@b26-idrt-9-2016-011],[@b27-idrt-9-2016-011] Commercially available antibiotic disks (HiMedia) were used for antimicrobial susceptibility testing. Susceptibility of isolates to penicillin G, ampicillin, oxacillin, cefotaxime, gentamycin, streptomycin, tetracycline, erythromycin, chloramphenicol, norfloxacin, amikacin, amoxiclav (ceftazidime/clavulanic acid), imipenem, ciprofloxacin, kanamycin, methicillin, and vancomycin was determined by the disk agar diffusion (DAD) technique. *S. aureus* ATCC 25923, an all-sensitive reference strain, was used as a quality control strain for the DAD test.

Antibacterial activity of eugenol
---------------------------------

### Determination of minimum inhibitory concentration

The minimum inhibitory concentration (MIC) was determined by a microdilution method, using Luria broth (HiMedia) according to the National Committee for Clinical Laboratory Standards with some modification.[@b28-idrt-9-2016-011],[@b29-idrt-9-2016-011] In brief, 10 µL of bacterial strain (SA-6) containing 2.5 × 10^5^ CFU/mL *S. aureus* cells were added individually to 1 mL of nutrient broth. Different concentrations (1, 2, 5, 10, 25, 50, 100, and 200 µg/mL) of eugenol (dissolved solution that accurately reflect the amount of eugenol available in solution to act on the microorganisms) were added to the test tubes containing the test strains. After 24 hours of incubation in shaking condition, the MIC values were obtained by checking the turbidity of the bacterial growth. The lowest concentration at which there was no visible turbidity was taken as the MIC of that nanoparticle. The MIC value corresponded to the concentration that inhibited 99% of bacterial growth.

### Determination of minimum bactericidal concentration

The minimum bactericidal concentration (MBC) of the eugenol was determined according to the standard method with some modifications.[@b29-idrt-9-2016-011] This is an extension part of the MIC experiment. The MBC values were determined by subculturing the MIC dilutions onto the sterile agar plates incubated at 37°C for 24 hours. The minimum concentration of the eugenol required for completely killing the tested bacteria was observed and tabulated as MBC level. The MBC value reflects 100% bacterial killing, compared with the positive control (no treatment).

### Tolerance level

The tolerance levels of the bacterial strain against eugenol were determined according to the standard method using the following formula:[@b30-idrt-9-2016-011] $$\text{Tolerance} = \text{MBC}/\text{MIC}.$$

### Disk agar diffusion

Susceptibility of eugenol to *S. aureus* strains was determined by the DAD technique according to Bauer et al.[@b26-idrt-9-2016-011] The test bacterium taken from an overnight culture (inoculated from a single colony) was freshly grown for four hours having 10^6^ CFU/mL were standardized against McFarland standard. With this culture, a bacterial lawn was prepared on Mueller-Hinton agar. Filter paper disks of 6 mm size were used to observe eugenol susceptibility. Water disks were used as control. Filter paper disks were prepared by absorbing 10 µL of drug from 2 mg/mL of eugenol and water, respectively. The diameter of the zone of bacterial growth inhibition surrounding the disk (including the disk) was measured.[@b29-idrt-9-2016-011]

### Intracellular reactive oxygen species generation

The intracellular reactive oxygen species (ROS) generation was measured by using 2,7-dichlorofluorescein diacetate (DCFH~2~-DA).[@b29-idrt-9-2016-011] The DCFH~2~-DA passively enters into the cell and reacts with ROS to form the highly fluorescent compound 2,7-dichlorofluorescein. In brief, *S. aureus* cells were treated with eugenol at their respective MIC concentrations for 24 hours. After treatment schedule, the cell pellet was collected, and a homogeneous suspension was made by phosphate-buffered saline (PBS) upto 1 mL, and then, the cells were incubated with 1 µg/mL DCFH~2~-DA for 30 minutes at 37°C in the dark condition. The cells were then washed three times and resuspended with fresh PBS. DCF fluorescence was observed by fluorescence microscopy (Nikon Eclipse LV100 POL). All measurements were done in triplicate and best images were represented in the article.

### Action of eugenol on cellular morphology

In 1 mL culture medium, *S. aureus* cells (10^6^ CFU/mL bacterial cells) were treated with eugenol at their respective MIC concentrations and incubated at 37 ± 2°C with shaking at 198 rpm for 24 hours. Control experiment was conducted in the absence of eugenol. At the end of 24 hours, the bacterial cultures were centrifuged and bacterial pellet was fixed with 50 µL of 2.5% glutaraldehyde and washes three times with 1 × PBS. A total of 50 µL PBS was added to this pellet to form a suspension. One drop of fixed pellet was taken on a glass plate and dried. Then, the sample was platinum coated for observation in a scanning electron microscope (SEM, Hitachi S-3000N).[@b29-idrt-9-2016-011]

Results and Discussion
======================

Identification of *S. aureus*
-----------------------------

From the study, it was observed that 55.55% (20) samples were gram positive and 44.44% (16) samples were gram negative. 100% (20) of gram-positive isolates are oxidase positive, catalase positive, coagulase positive, latex agglutination positive, thermonuclease positive, positive mannitol fermentation activity, and positive hemolytic activity and 100% of gram-positive samples were nonmotile in nature ([Table 1](#t1-idrt-9-2016-011){ref-type="table"}).

Gram-negative clinical isolates were not involved in this study, only gram-positive isolates were involved as it is commonly known that *S. aureus* is gram-positive bacteria. Clinical isolates were gram positive, which may be due to the thicker peptidoglycan layers of their cell walls; iodine penetrates the cell wall of the bacteria and alters the blue dye to inhibit its diffusion through the cell wall during the decolorization process.[@b18-idrt-9-2016-011] They were spherical cells arranged in irregular clusters resembling a bunch of grapes in gram staining. 100% (20) of gram-positive isolates are oxidase positive because of the presence of *N*,*N*,*N*′,*N*′-tetramethyl-*p*-phenylenediamine dihydrochloride as an artificial electron acceptor, which takes electron from cytochrome oxidase in the electron transport chain and changes its color to dark blue.[@b19-idrt-9-2016-011] 100% of oxidase-positive isolates were catalase positive and coagulase positive but 100% of oxidase-positive isolates were nonmotile and gave positivity in latex agglutination test. The catalase test is used to detect an organism's ability to produce catalase enzyme. In a clinical setting, the catalase test can be used to differentiate various gram-positive cocci, such as among the *Staphylococci* and *Streptococci*, and confirm the identification of various pathogens. Here, isolates were catalase positive due to the production of catalase enzyme, which catalyzes H~2~O~2~, a potent oxidizing agent into water and oxygen.[@b20-idrt-9-2016-011] *S. aureus* bacterial strains generally produces different proteins such as α- and γ-hemolysin, enterotoxins A and B, coagulase, and TSST-1, here isolates were coagulase positive due to the production of coagulase enzyme, which reacts with prothrombin to form staphylothrombin that causes blood to clot by converting fibrinogen to fibrin.[@b21-idrt-9-2016-011] Due to the absence of flagellum, the clinical isolates were nonmotile. Positivity in latex agglutination test was due to the interaction of human antibody attached to the latex particles with protein A bound to the bacterial cell surface or interaction between cell-associated clumping factor and plasma constituents adsorbed to the latex particles.[@b17-idrt-9-2016-011] 100% of gram-positive and oxidase-positive isolates had potent thermonuclease activity, mannitol fermentation activity, and hemolytic activity. Isolates have hemolytic activity due to the production of hemolysin by isolates, which binds with the hemolysin receptor present on the surface of RBCs that favor hemolysis and make the clear zone surrounding the isolates.[@b3-idrt-9-2016-011] Latex agglutination activity, hemolytic activity, thermonuclease activity, mannitol fermentation activity, and non-motility of clinical isolates suggest that these may be *S. aureus*. Thus, among 36 clinical samples, 20 isolates (55.55%) were confirmed to be *S. aureus* strains. Thermonuclease activity of the isolates may be due to the breakdown of DNA present in the media by the production of nuclease enzyme. Nuclease production, coagulase positivity, and hemolytic activity suggested that the strains were pathogenic in type. The clinically isolated *S. aureus* strains were newly named as SA (*S. aureus*) from SA1 to SA20.

Antibiotic susceptibility testing
---------------------------------

The antibiotic resistance profile of the isolated bacterial strains was revealed by the DAD test ([Table 2](#t2-idrt-9-2016-011){ref-type="table"}). The results revealed that out of 20 gram-positive isolated strains, 100% isolated strains were resistant to penicillin G, ampicillin, cefotaxime, oxacillin, and amoxiclav antibiotics and 100% isolated strains were sensitive to gentamycin, amikacin, and imipenem. Of all *S. aureus* isolated strains, 95% were resistant to methicillin, 75% resistant to ciprofloxacin, 65% resistant to erythromycin, 30% resistant to tetracyclin and vancomycin, 20% resistant to streptomycin and norfloxacin antibiotics, 15% resistant to chloramphenicol, and 10% resistant to kanamycin ([Table 2](#t2-idrt-9-2016-011){ref-type="table"}). The bacterial strains with resistance to three or more antibiotics are considered as multidrug-resistant (MDR) strains. From this study, it was revealed that 100% *S. aureus* isolated strains were MDR strains. They have different types of resistance pattern among MDR strains. Among the 20 MDR *S. aureus* strains, 5% strains were resistant to 5 antibiotics, 10% strains to 6 antibiotics, 20% strains to 7 antibiotics, 20% strains to 8 antibiotics, 10% strains to 9 antibiotics, 20% to 10 antibiotics, and 15% strains to ≥11 antibiotics. [Figure 1](#f1-idrt-9-2016-011){ref-type="fig"} shows the graphical representation of antibiotic susceptibility profile of *S. aureus.* These *S. aureus* strains are resistant to β-lactam antibiotics, aminoglycosides, quinolones, macrolides, tetracycline, chloramphenicol, and vancomycin. This resistance may be due to the structural modification by enzymatic action that causes inactivation of the antibiotic; due to altering the outer membrane permeability, the access to target was prevented; antibiotic target site was altered and efflux pumps may be involved, which pumps out the antibiotic and target enzyme bypass or over production.[@b31-idrt-9-2016-011]

Multiple antibiotic resistance (MAR) index of *S. aureus* shows that 85% strains had an MAR index of ≥0.4 and only 15% strains had an MAR index of \<0.4 ([Table 3](#t3-idrt-9-2016-011){ref-type="table"}). MAR index \> 0.2 indicates the isolates originating from other sources where antibiotics were often used.[@b32-idrt-9-2016-011],[@b33-idrt-9-2016-011] However, the MAR values can be viewed as an indication of the extent of microbial exposure to antibiotics used within the community. Treatment of antibiotic-resistant bacteria is a therapeutic problem. Susceptibility pattern is useful to determine the future challenges of effective therapy.

Antibacterial activity of eugenol
---------------------------------

### Determination of MIC and MBC

Antimicrobial activity of eugenol against isolated *S. aureus* strains at different concentrations showed a strong dose-dependent antimicrobial activity ([Fig. 2](#f2-idrt-9-2016-011){ref-type="fig"}). From this study, it was found that, as the concentration of eugenol was increased, microbial growth decreases. Particular phytochemical concentration was noted where no visible growth appears in broth culture, which is considered as MIC concentration. The MIC value of gram-positive *S. aureus* strain was 100 µg/mL. To avoid the misinterpretations due to the turbidity of insoluble compounds and color of the drug in broth dilution tube, MBC was determined by culturing the MIC dilutions on the sterile agar plates. The particular phytochemical concentration was noted where no visible growth appears on agar plate, which is considered as MBC concentration. The MBC value was 200 µg/mL against *S. aureus* strain ([Fig. 2](#f2-idrt-9-2016-011){ref-type="fig"}). From these results, we can suggest that inhibition of bacterial growths or bacterial killing were noted due to the penetration of eugenol into the bacterial cell that inhibits the growth of the bacteria and acts as a bactericidal agent followed by bacteriostatic activity. Eugenol is a monocyclic, oxygenated, aromatic monoterpene like menthol. It shows highly active antimicrobial activity. Several reports on the antimicrobial activity of some monoterpenes showed that the number of double bonds in the structure and acyclic, monocyclic, and/or bicyclic structure has no significant influence on its activity, but in this experience aromatic monoterpenes (carvacrol, eugenol, and thymol) showed the best inhibitory activity.[@b34-idrt-9-2016-011],[@b35-idrt-9-2016-011] The gram-positive *S. aureus* showed similar behaviors against the terpene. These terpenes could penetrate through the exopolysaccharide layer and maintain the inhibitory and bactericidal effects. In the future, eugenol could be used for therapeutical formulations in the replacement of antibiotic to treat diseases caused by resistant *S. aureus*. The observed results in our study seem to be quite similar to those previously reported. Qiu et al reported that the essential clove oil component including eugenol kills the microbes and inhibits the virulence factor at similar doses.[@b36-idrt-9-2016-011]

### Tolerance level

The MBC/MIC ratio is a parameter that reflects the bactericidal capacity of the analyzed compound. The tolerance level of isolated *S. aureus* strain toward eugenol was calculated from the respective MIC and MBC values. In *S. aureus* strain, the tolerance level was 2 when charged with eugenol. Bactericidal agents kill total microbes, whereas bacteriostatic agents simply inhibit the bacterial growth. When MBC/MIC ratio is ≥16 for bacterial strains, the agent is considered bacteriostatic in type, and when this ratio is ≤4, the agent is considered bactericidal.[@b37-idrt-9-2016-011] MBC is usually identical to or within 1 or 2 doubling dilutions of the MIC; if the MBC exceeds the MIC by 32-fold or more, the microbe is defined as tolerant.[@b29-idrt-9-2016-011] In our study, eugenol exerted a bactericidal effect against *S. aureus* strains because the MBC/MIC ratio values were 2.

### Disk agar diffusion

This was evident from the study that the diameter of the zone of inhibition obtained significance during the assessment of antibacterial activity. The inhibition zones of *S. aureus* against eugenol and distilled water as control are shown in [Figure 3](#f3-idrt-9-2016-011){ref-type="fig"}. In agar diffusion test, the diameter of the inhibition zone of eugenol toward *S. aureus* is 14 mm. No zone of inhibition was observed in the control disk. A plant-derived phytochemical known as eugenol showed potent function in the inhibition of growth of well-known pathogenic bacteria. This phytomedicine has really proved to be beneficial to minimize the total microbial growth inhibition.

### Intracellular ROS generation

In the *S. aureus* cell, eugenoltriggered cytotoxicity has been encountered by the generation of ROS. Here, we measure the intracellular ROS; DCFH~2~-DA was used as intracellular ROS indicator for the eugenoltreated cells. After exposed to the phytochemical, bacterial cells were stained with DCFH~2~-DA for 30 minutes. Results revealed that the eugenol-treated *S. aureus* bacteria became DCF+, indicating that ROS were generated and participated in the eugenol-mediated cell death ([Fig. 4](#f4-idrt-9-2016-011){ref-type="fig"}) without eugenol treatment referred as control where no fluorescent cell was found, indicating no ROS generation. From these results, we believe that the anti *S. aureus* ability of the eugenol involves the generation of intracellular ROS. Elevation of ROS is the main candidate mediator for bacterial death. The ROS generation was caused by the impeded electronic transport along the respiratory chain in the damaged plasma membrane.[@b38-idrt-9-2016-011] The underlying mechanisms of ROS production in eugenol-treated cells will be further explored in detail.

### Action of eugenol on cellular morphology

The cellular surface morphology was studied by SEM. The micrograph by SEM of *S. aureus* cells treated and untreated with eugenol are displayed in [Figure 5](#f5-idrt-9-2016-011){ref-type="fig"}. In SEM, eugenol was observed in the membrane of the bacteria as well as in the interior of the bacteria. SEM images explore the distribution and the exact location of the drug as well as the structural morphology of the bacterial cells after and before treatment with eugenol. Results showed that the surface of control bacterial cells (untreated cells; [Fig. 5A](#f5-idrt-9-2016-011){ref-type="fig"}) was smooth, intact, and showed typical characters of surface, while the treated cells ([Fig. 5B](#f5-idrt-9-2016-011){ref-type="fig"}) were damaged severely. Some cells showed large leakage, others misshapen and fragmentary, many pits and gaps appeared in the images, and their membrane was fragmented. The mechanism by which eugenol is able to penetrate the bacteria is not understood completely, but studies suggest that when bacterial cells were treated with eugenol, changes took place in its membrane morphology that produced a significant increase in its permeability, affecting proper transport through the plasma membrane, leaving the bacterial cells incapable of properly regulating transport through the plasma membrane, and resulting into cell death. These findings suggest the possible antibacterial mechanisms by which eugenol inhibits bacterial growth, as well as cellular responses. Eugenol entered into the cell and produced ROS, thus inhibiting the growth of cells. Simultaneously, eugenol may affect some cellular components to induce the collapse of membrane, resulting in cell decomposition and death eventually.[@b29-idrt-9-2016-011] However, it can be anticipated that eugenol by acting on cellular membrane and ROS generation will cause the disruption of cell membrane, including the DNA damage impairing the cell death.[@b39-idrt-9-2016-011]

Summary and Conclusion
======================

The MDR *S. aureus* is a cause of concern to the clinicians as well as the microbiologist, particularly the vancomycin-resistant *S. aureus*. Sensitivity profile of the bacteria is essential for the perfect choice of antimicrobial agents for appropriate empirical treatment. In the present study, it was confirmed that several *S. aureus* strains are already resistant to the latest drug vancomycin; eugenol effectively kills the vancomycin-resistant *S. aureus* strains via the production of ROS generation and membrane damage. So, we suggest the use of eugenol as the drug of choice for vancomycin-resistant *S. aureus* causing life-threatening infections. The phytochemical eugenol should be used as a reserve drug only in cases of vancomycin-resistant strains. More research is needed to understand the mechanism of action and increase the effectiveness of eugenol for the use of eugenol as antibiotics.
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###### 

Standard biochemical tests of clinical isolates collected from pus sample.

  SAMPLE NO.   GRAM STAIN   OXIDASE   CATALASE   COAGULASE TEST   MOTILITY   LATEX AGGLUTINATION TEST   THERMONUCLEASE ACTIVITY   HEMOLYSIS ON BLOOD AGAR   GROWTH ON MSA   ISOLATES NAME
  ------------ ------------ --------- ---------- ---------------- ---------- -------------------------- ------------------------- ------------------------- --------------- ---------------
  S1           +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA1
  S2           −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S3           −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S4           +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA2
  S5           +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA3
  S6           −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S7           +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA4
  S8           +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA5
  S9           −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S10          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA6
  S11          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA7
  S12          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA8
  S13          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S14          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S15          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S16          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA9
  S17          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA10
  S18          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S19          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S20          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA11
  S21          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S22          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA12
  S23          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S24          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S25          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA13
  S26          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA14
  S27          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA15
  S28          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S29          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA16
  S30          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA17
  S31          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA18
  S32          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S33          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA19
  S34          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND
  S35          +ve          +ve       +ve        +ve              −ve        +ve                        +ve                       +ve                       +ve             SA20
  S36          −ve          ND        ND         ND               ND         ND                         ND                        ND                        ND              ND

**Notes:** ND, tests are not done; +ve, tests are positive; −ve, tests are negative.

###### 

Antimicrobial susceptibility testing of 20 isolates of *S. aureus.*

  ANTIBIOTICS       SENSITIVE NO. (%)   RESISTANT NO. (%)
  ----------------- ------------------- -------------------
  Penicillin G      0/20 (0%)           20/20 (100%)
  Gentamycin        20/20 (100%)        00/20 (0%)
  Streptomycin      16/20 (80%)         04/20 (20%)
  Ampicillin        00/20 (0%)          20/20 (100%)
  Tetracyclin       14/20 (70%)         06/20 (30%)
  Erythromycin      07/20 (35%)         13/20 (65%)
  Amikacin          20/20 (100%)        00/20 (0%)
  Chloramphenicol   17/20 (85%)         03/20 (15%)
  Ciprofloxacin     05/20 (25%)         15/20 (75%)
  Cefotaxime        00/20 (0%)          20/20 (100%)
  Kanamycin         18/20 (90%)         02/20 (10%)
  Oxacillin         00/20 (0%)          20/20 (100%)
  Norfloxacin       16/20 (80%)         04/20 (20%)
  Imipenem          20/20 (100%)        00/20 (0%)
  Amoxiclav         00/20 (0%)          20/20 (100%)
  Methicillin       01/20 (5%)          19/20 (95%)
  Vancomycin        14/20 (70%)         6/20 (30%)

###### 

MAR index of *S. aureus* isolates.

  MAR INDEX   NO. OF ISOLATES   PERCENTAGE (%)
  ----------- ----------------- ----------------
  0.0         00                00.00
  0.1         00                00.00
  0.2         01                05.00
  0.3         02                10.00
  0.4         08                40.00
  0.5         06                30.00
  0.6         01                05.00
  0.7         02                10.00
  0.8         00                00.00
  0.9         00                00.00
  1.0         00                00.00
